Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2009 8
2010 2
2011 1
2012 7
2013 6
2014 6
2015 3
2016 7
2017 4
2018 3
2019 2
2020 3
2021 10
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: Meta-Analysis, Review, Systematic Review, in the last 10 years. Clear all
Page 1
Degarelix.
[No authors listed] [No authors listed] 2023 May 28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 May 28. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643893 Free Books & Documents. Review.
Degarelix is a parenterally administered, gonadotropin releasing hormone (GnRH) antagonist that effectively blocks androgen production and is used to treat advanced prostate cancer. Degarelix therapy is associated with serum enzyme elevations during therapy, but has …
Degarelix is a parenterally administered, gonadotropin releasing hormone (GnRH) antagonist that effectively blocks androgen productio …
Degarelix for treating advanced hormone-sensitive prostate cancer.
Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blümle A, Schmucker C, Mayer B, Kunath F. Zengerling F, et al. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2. Cochrane Database Syst Rev. 2021. PMID: 34350976 Free PMC article. Review.
BACKGROUND: Degarelix is a gonadotropin-releasing hormone antagonist that leads to medical castration used to treat men with advanced or metastatic prostate cancer, or both. ...Degarelix likely results in an increase in injection site pain compared to standard andro …
BACKGROUND: Degarelix is a gonadotropin-releasing hormone antagonist that leads to medical castration used to treat men with advanced …
Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L, Whyte S, Gomersall T, Ren S, Wong R, Chambers D, Tappenden P. Uttley L, et al. Pharmacoeconomics. 2017 Jul;35(7):717-726. doi: 10.1007/s40273-016-0481-1. Pharmacoeconomics. 2017. PMID: 27943135 Free article. Review.
As part of its Single Technology Appraisal Process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of degarelix (Ferring Pharmaceuticals) to submit evidence for the clinical and cost effectiveness of degarelix for the treatment …
As part of its Single Technology Appraisal Process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of …
Questionable oncologic benefits of degarelix.
Secin FP. Secin FP. Urol Oncol. 2016 Oct;34(10):423-6. doi: 10.1016/j.urolonc.2016.05.029. Epub 2016 Jun 28. Urol Oncol. 2016. PMID: 27364704 Review.
INTRODUCTION: Luteinizing hormone releasing hormone (LhRh) antagonist degarelix has been approved by the Food and Drug Administration (FDA) for the treatment of advanced prostate cancer in 2008. ...CONCLUSION: The flawed methodology of these publications makes the evidence …
INTRODUCTION: Luteinizing hormone releasing hormone (LhRh) antagonist degarelix has been approved by the Food and Drug Administration …
Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
Clinton TN, Woldu SL, Raj GV. Clinton TN, et al. Expert Opin Pharmacother. 2017 Jun;18(8):825-832. doi: 10.1080/14656566.2017.1328056. Epub 2017 May 19. Expert Opin Pharmacother. 2017. PMID: 28480768 Free PMC article. Review.
Areas covered: This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its role in the management of advanced prostate cancer, the clinical evidence supporting its regulatory approval, as well as potential benefits …
Areas covered: This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its …
The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.
Sari Motlagh R, Abufaraj M, Mori K, Aydh A, Rajwa P, Katayama S, Grossmann NC, Laukhtina E, Mostafai H, Pradere B, Quhal F, Karakiewicz PI, Enikeev DV, Shariat SF. Sari Motlagh R, et al. Eur Urol Oncol. 2022 Apr;5(2):138-145. doi: 10.1016/j.euo.2021.07.002. Epub 2021 Jul 21. Eur Urol Oncol. 2022. PMID: 34301529 Free article. Review.
CONTEXT: Degarelix is associated with high rates of injection site reaction. ...In the ranking analyses, degarelix achieved the worst rank of all AEs and the best rank of serious AEs. ...
CONTEXT: Degarelix is associated with high rates of injection site reaction. ...In the ranking analyses, degarelix achieved th …
A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone-releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix).
Bahl A, Rajappa S, Rawal S, Bakshi G, Murthy V, Patil K. Bahl A, et al. Indian J Cancer. 2022 Mar;59(Supplement):S160-S174. doi: 10.4103/ijc.IJC_1415_20. Indian J Cancer. 2022. PMID: 35343199 Free article. Review.
Degarelix causes no initial flare, therefore it is recommended in patients with spinal metastases or ureteric obstruction. ...There is considerable long-term evidence for goserelin in patients with advanced PCa, with degarelix being a more recent option. The availab …
Degarelix causes no initial flare, therefore it is recommended in patients with spinal metastases or ureteric obstruction. ...There i …
Does Exist a Differential Impact of Degarelix Versus LHRH Agonists on Cardiovascular Safety? Evidences From Randomized and Real-World Studies.
Sciarra A, Busetto GM, Salciccia S, Del Giudice F, Maggi M, Crocetto F, Ferro M, De Berardinis E, Scarpa RM, Porpiglia F, Carmignani L, Damiano R, Artibani W, Carrieri G. Sciarra A, et al. Front Endocrinol (Lausanne). 2021 Jun 14;12:695170. doi: 10.3389/fendo.2021.695170. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34194398 Free PMC article. Review.
The Randomized trials analyzed in this paper sustain a possible protective role for degarelix versus LHRH agonists in reducing the rate of new CV events and interventions in the short-term period. On the contrary, real-word data are contradictory in different national expe …
The Randomized trials analyzed in this paper sustain a possible protective role for degarelix versus LHRH agonists in reducing the ra …
Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
Klotz L. Klotz L. Expert Opin Drug Metab Toxicol. 2015;11(11):1795-802. doi: 10.1517/17425255.2015.1085506. Epub 2015 Oct 29. Expert Opin Drug Metab Toxicol. 2015. PMID: 26513436 Review.
However, their limitations include a transient initial rise in testosterone, failure to reduce testosterone to castrate levels in some patients, incomplete suppression of follicle-stimulating hormone (FSH), and an increased risk of cardiovascular (CV) events in those with pre-exi …
However, their limitations include a transient initial rise in testosterone, failure to reduce testosterone to castrate levels in some patie …
40 results